ライフサイエンスコーパス: blood pressure

1 p=0.0003 for systolic and p=0.0001 diastolic blood pressure).

2 did not show consistent efficacy in reducing blood pressure.

3 patients, which was correlated with systolic blood pressure.

4 , and caffeine was associated with a rise in blood pressure.

5 s of cerebral perfusion pressure or arterial blood pressure.

6 te decline and proteinuria without affecting blood pressure.

7 tistically significant albeit weak impact on blood pressure.

8 ansport is a final step in the regulation of blood pressure.

9 control versus standard control of systolic blood pressure.

10 magnitude irregular fluctuations of systemic blood pressure.

11 on between variation at the SLC4A7 locus and blood pressure.

12 lus spp., increased TH17 cells and increased blood pressure.

13 uced in saturated fat and cholesterol, lower blood pressure.

14 treated or achieve adequate control of their blood pressure.

15 ed body composition, blood biochemistry, and blood pressure.

16 to -2.5; 6 studies; I2 = 17%) for diastolic blood pressure.

17 , GE) and compared in terms of age, sex, and blood pressure.

18 (WNK4) regulates electrolyte homeostasis and blood pressure.

19 potassium intake are associated with higher blood pressure.

20 , HDL-c, glucose, and systolic and diastolic blood pressure.

21 r than one in twelve are in control of their blood pressure.

22 mRNA levels strongly correlate with maternal blood pressure.

23 t disease risk extended beyond its effect on blood pressure.

24 long with clinically important reductions in blood pressure.

25 d shown individual association with systolic blood pressure.

26 ist did not completely block the increase in blood pressure.

27 -thyroid axes, as well as a rise in systolic blood pressure.

28 es, including overweight or obesity and high blood pressure.

29 oendocrine cells, with effects on control of blood pressure.

30 and hyperlipidemia and have higher discharge blood pressures.

31 t influence blood lipids and lipoproteins or blood pressures.

32 nd diastolic (2.25 mm Hg; 95% CI, 0.83-3.67) blood pressures.

33 The correlation was low for systolic blood pressure (0.39; P<0.0001).

34 for HRV with heart rate (-0.74<rg<-0.55) and blood pressure (-0.35<rg<-0.20).

35 to -0.75]; 22 trials [n = 57953]), diastolic blood pressure (-0.49 mm Hg [95% CI, -0.82 to -0.16]; 23

36 = 1.6, 95% CI = 1.2-2.3), increased systolic blood pressure (1.2 per 20mmHg, 95% CI = 1.1-1.4), nondi

37 ical hypothyroidism was associated with high blood pressure (1.24; 1.04-1.48) and high serum triglyce

38 between-group mean differences for systolic blood pressure (-1.26 mm Hg [95% CI, -1.77 to -0.75]; 22

39 actorial design to target levels of systolic blood pressure (130-149mmHg vs <130mmHg; open label) and

40 d ratio=0.79 [95% CI: 0.68-0.92] at systolic blood pressure 160 vs 110 mm Hg) but not for diastolic b

41 % for abdominal obesity, 44.05% for elevated blood pressure, 40.98% for reduced HDL-cholesterol, 23.3

42 ors assessed were as follows: tobacco 92.9%; blood pressure 51.2%; body mass index 33.8%; low-density

43 height and weight (96% versus 63%; P<0.001), blood pressure (86% versus 39%; P<0.001), left ventricul

44 diovascular and metabolic outcomes (eg, high blood pressure, abnormal lipid levels, and insulin resis

45 014), with continuous monitoring of arterial blood pressure (ABP) and intracranial pressure (ICP), we

46 ubiquitous peptide that can elevate arterial blood pressure (ABP) yet understanding of the mechanisms

47 timate the prevalence of abnormal ambulatory blood pressure (ABP), assess factors associated with abn

48 rprisingly, PLD2 (-/-) mice exhibit elevated blood pressure accompanied by associated changes in card

49 significantly higher systolic and diastolic blood pressures among those who entered or consistently

50 6 to -4.2; 6 studies; I2 = 51%) for systolic blood pressure and -4.0 mm Hg (95% CI, -5.6 to -2.5; 6 s

51 As an add-on to losartan, Ly normalized blood pressure and albuminuria, and prevented CKD progre

52 ount for some of the missing heritability of blood pressure and are generally relevant to SNP associa

53 s associated with better control of systolic blood pressure and attenuation of decline in both grip s

54 vascular risk factors too, such as increased blood pressure and body weight.

55 PEX are more likely to require attention to blood pressure and cardiac morbidity.

56 sed the determinants of screening uptake for blood pressure and cholesterol level checks.

57 e of incorporating information from repeated blood pressure and cholesterol measurements to predict c

58 MSNA, blood pressure and heart rate (HR) were recorded in age-

59 Blood pressure and heart rate remained stable in all coh

60 regulation of sympathetic activity and thus blood pressure and heart rate was determined using a mou

61 -AR blockade, LV volumes were unchanged but blood pressure and heart rate were reduced in both group

62 iency of Kir2.1 channels results in elevated blood pressure and increased vascular resistance.

63 High sodium intake is known to increase blood pressure and is difficult to measure in epidemiolo

64 focus is on cardiovascular traits including blood pressure and lipids, and lifestyle factors includi

65 ery, PEX was associated with higher systolic blood pressure and more frequent ECG abnormalities but n

66 Reducing sodium intake can decrease blood pressure and prevent hypertension.

67 ght into the genetic mechanisms that control blood pressure and provide a potential target for indivi

68 understand the indirect effects of systolic blood pressure and serum aldosterone on the relationship

69 ed measures of anthropometry, lung function, blood pressure and standard blood-based biomarkers.

70 opometric data [anthropometric measurements, blood pressure and total body fat distribution] of these

71 Tail cuff blood pressure and uterine artery Doppler ultrasound wer

72 EEG, EMG, blood pressure and WBP signals were simultaneously recor

73 rs (mainly tobacco use, lipids, and elevated blood pressure) and societal level health determinants (

74 ciation between urinary sodium excretion and blood pressure, and an inverse association between urina

75 HGA levels, plasma glucose levels, diastolic blood pressure, and body mass index.

76 permy, allowing fluid secretion, controlling blood pressure, and enabling gastrointestinal activity.

77 the potential intermediates of blood lipids, blood pressure, and glycemic phenotypes.

78 l examination findings, heart rate, systolic blood pressure, and haemoglobin concentration strongly d

79 cal (body-mass index, systolic and diastolic blood pressure, and handgrip strength), behavioural (smo

80 f IV acetaminophen on core body temperature, blood pressure, and heart rate in febrile critically ill

81 Changes-over-time temperature, blood pressure, and heart rate outcomes were also signif

82 Heart rate, blood pressure, and heart rate variability were assessed

83 e between all diets on inflammation markers, blood pressure, and insulin-glucose homeostasis.The resu

84 clinical practice guidelines on cholesterol, blood pressure, and overweight/obesity.

85 Quality of life, blood pressure, and polysomnography were similar between

86 d adjusted time-weighted average heart rate, blood pressure, and respiratory rate, along with changes

87 al effect of mineralocorticoids on survival, blood pressure, and vascular reactivity, associated with

88 in regulating extracellular fluid volume and blood pressure, as well as airway surface liquid volume

89 laboratory tests, such as the Fuster-BEWAT (blood pressure [B], exercise [E], weight [W], alimentati

90 severity score, Glascow Coma Scale, systolic blood pressure, base excess, platelet count, hemoglobin,

91 V), circulating angiogenic cells (CACs), and blood pressure before and 2 h after the ingestion of tes

92 ith nonischemic HF etiology, higher baseline blood pressure, better baseline renal function, and fewe

93 t for age, sex, diabetes diagnosis, systolic blood pressure, BMI, smoking status, estimated glomerula

94 siniferatoxin, selectively lowered diastolic blood pressure both at daytime and night-time with less

95 ffects of chronic IH on breathing along with blood pressure (BP) and assessed whether the autonomic r

96 Secular trends in blood pressure (BP) and body mass index (BMI) during chi

97 ympathetic nerve activity (MSNA), continuous blood pressure (BP) and electrocardiography were measure

98 It is unclear whether intensive lowering of blood pressure (BP) at the acute phase of intracerebral

99 Data are sparse regarding which blood pressure (BP) components in young adulthood optima

100 r, <50% of thiazide-treated patients achieve blood pressure (BP) control.

101 d hypertension (MHT), defined as nonelevated blood pressure (BP) in the clinic setting and elevated B

102 Blood pressure (BP) is regulated at the central nervous

103 It is currently unknown whether intensive blood pressure (BP) lowering beyond that recommended wou

104 domised controlled trials of early intensive blood pressure (BP) lowering in patients with ICH (<6 ho

105 We proposed to determine whether aggressive blood pressure (BP) lowering prevents recurrent atrial f

106 oscillometric devices for monitoring central blood pressure (BP) maintain the cuff pressure at a cons

107 tanding of the contribution of C1 neurons to blood pressure (BP) regulation derives predominantly fro

108 Since endothelin-1 (ET-1) is implicated in blood pressure (BP) regulation, we hypothesized that E2'

109 control of resting metabolic rate (RMR) and blood pressure (BP) through its actions in the arcuate n

110 ease (CVD) risk instead of or in addition to blood pressure (BP) to guide antihypertensive treatment

111 Intensive blood pressure (BP) treatment can avert cardiovascular d

112 Blood pressure (BP) was directly measured by the arteria

113 sured using validated scales, and ambulatory blood pressure (BP) was measured every 15 minutes during

114 ons: 1) Is there evidence that self-measured blood pressure (BP) without other augmentation is superi

115 ransport by the renal tubule is critical for blood pressure (BP), acid-base, and potassium homeostasi

116 In adults, high blood pressure (BP), adverse serum lipids, and smoking a

117 viduals without hypertension based on clinic blood pressure (BP), it is unclear who should be screene

118 harbor DNA sequence variants that influence blood pressure (BP).

119 tial reduction in ADHF events from intensive blood pressure [BP] treatment among the 6 key, prespecif

120 ase in sodium intake has been shown to lower blood pressure, but data from cohort studies on the asso

121 ment was associated with a small increase in blood pressure, but was devoid of major side effects and

122 with MESA, HealthLNK overestimated systolic blood pressure by 6.5 mm Hg (95% confidence interval, 4.

123 All approaches achieved target blood pressure by 60 minutes.

124 9), patient-reported satisfaction with their blood-pressure care and blood-pressure medications, and

125 Satisfaction with blood-pressure care was high in both treatment groups, a

126 emonstrated significantly increased systemic blood pressure, CBF and PbrO2 at the hyperacute phase of

127 effect of the cholesterol level check on the blood pressure check and vice versa.

128 and weight management) and CVD risk factor (blood pressure, cholesterol and blood lipids, glycemic c

129 agement targeting an individualized systolic blood pressure, compared with standard management, reduc

130 in cholesterol <70 mg/dL or statin therapy), blood pressure control (<140 mm Hg systolic, <90 mm Hg d

131 ion, skeletal muscle pump was found to drive blood pressure control (EMG --> SBP) as well as control

132 LA dilatation may be mediated by blood pressure control and the development of visceral a

133 association with use of these medicines and blood pressure control in countries at varying levels of

134 iometabolic events and death, independent of blood pressure control, than for patients with essential

135 rations in microbial communities relevant in blood pressure control.

136 In this simulation study, intensive systolic blood-pressure control prevented cardiovascular disease

137 y (1.53, 1.13-2.07; p=0.054), and have their blood pressure controlled (2.06, 1.69-2.50; p<0.0001) th

138 ive ability in youth), BMI, height, systolic blood pressure, coronary artery disease, and type 2 diab

139 ored weekly, and 10% reported checking their blood pressure daily and 43% took their medications as p

140 (Dietary Patterns, Sodium Intake and Blood Pressure [DASH-Sodium]; NCT00000608).

141 ilar for each 10 mmHg increment in diastolic blood pressure (DBP) (p < 0.001) or each 15 mmHg increme

142 systolic blood pressure (SBP) and diastolic blood pressure (DBP) in healthy individuals.A systematic

143 er and less than 180 mm Hg, office diastolic blood pressure (DBP) of 90 mm Hg or greater, and a mean

144 The change in diastolic blood pressure (DBP) over time was significantly differe

145 The mean diastolic blood pressure (DBP) was lower in men with asthma than i

146 In individuals with a low diastolic blood pressure (DBP), the potential benefits or risks of

147 systolic blood pressure (SBP) and diastolic blood pressure (DBP).

148 Over 3 months, systolic blood pressure decreased, and estimated glomerular filtr

149 based risk score included age, sex, smoking, blood pressure, diabetes, and total cholesterol; in the

150 Mean velocity index based on arterial blood pressure did not reach statistical significance fo

151 Adjustment for coinciding change in blood pressure did not substantively alter the associati

152 e revealed higher variance in heart rate and blood pressure during rest and activity compared to wild

153 Blood pressure, ECG, oxygen levels, heart rate, CBC, and

154 ldren and Adolescents from the National High Blood Pressure Education Program.

155 diabetes therapeutics that are devoid of the blood pressure effects associated with canonical APJ act

156 of 20-HETE-dependent hypertension prevented blood pressure elevation and 20-HETE-mediated increases

157 tial for worsening CVD risk factors (such as blood pressure elevation, insulin resistance, and lipid

158 , podocyte injury and apoptosis, but without blood pressure elevation.

159 rides, fat mass (FM), systolic and diastolic blood pressure, fasting insulin and glucose, and homeost

160 Blood pressure (finger photoplethysmography), heart rate

161 The change in mean ambulatory nighttime blood pressure from randomization showed a benefit for d

162 with resistant hypertension (office systolic blood pressure >/=160 mm Hg despite taking at least thre

163 nverse association was observed for systolic blood pressure (hazard ratio=0.79 [95% CI: 0.68-0.92] at

164 iability including the expected variation in blood pressure, heart rate, and cortisol.

165 as associated with BMI, waist circumference, blood pressure, heart rate, HbA1c, blood glucose, LDL-to

166 established the cardiac threat posed by high blood pressure, high cholesterol, smoking, obesity, phys

167 following stratification, including systolic blood pressure, history of diabetes mellitus or peripher

168 eter diameter, 1.43; 95% CI, 1.09-1.86), and blood pressure (HR per 10 mm Hg, 0.87; 95% CI, 0.78-0.98

169 Achievement of ideal blood pressure, ideal body mass index, ideal glucose con

170 soconstriction and prolonged the increase in blood pressure in anaesthetised rats.

171 and night-time with less effect on systolic blood pressure in CHF rats.

172 fined according to the Fourth Report on High Blood Pressure in Children and Adolescents from the Nati

173 To evaluate the correlation and agreement of blood pressure in HealthLNK in comparison with in-person

174 tivate platelets and neutrophils and elevate blood pressure in mice.

175 affecting the ventricular refractoriness or blood pressure in pigs subjected to 7 days atrial tachyp

176 apelin-36(L28A) lost the ability to suppress blood pressure in spontaneously hypertensive rats (SHR).

177 tion between urinary potassium excretion and blood pressure, in a nationally representative sample of

178 sterone system genes associate with systolic blood pressure individually in both sexes, individually

179 ls have failed to show clear improvements in blood pressure, insulin sensitivity, or lipid parameters

180 previously published results of the Systolic Blood Pressure Intervention Trial showed that among part

181 (95% CI, 18.5-20.5) met the SPRINT (Systolic Blood Pressure Intervention Trial) eligibility criteria

182 tes mellitus from the SPRINT trial (Systolic Blood Pressure Intervention Trial): 4086 randomly assign

183 High blood pressure is a strong risk factor for cardiovascula

184 Elevated blood pressure is the leading heritable risk factor for

185 Detection, Evaluation, and Treatment of High Blood Pressure (JNC7).

186 etabolic traits (BMI, systolic and diastolic blood pressure, LDL cholesterol, HDL cholesterol, total

187 : Dysfunctions in CNS regulation of arterial blood pressure lead to an increase in sympathetic nerve

188 s association is independent of the attained blood pressure level because the J curve aligns with the

189 udies for identifying novel genetic loci for blood pressure, lipids, hypertension, etc.

190 ression quantitative trait locus analysis of blood pressure loci showed enrichment in aorta and tibia

191 dependent variants at 11 previously reported blood pressure loci.

192 th self-reported IHD, systolic and diastolic blood pressure, low-density lipoprotein- and total chole

193 longer hemodialysis vintage, lower systolic blood pressure, lower ultrafiltration rates, higher leuk

194 r the renal protection, independent from its blood pressure lowering effect, have not yet been fully

195 a quadpill-a single capsule containing four blood pressure-lowering drugs each at quarter-dose (irbe

196 The pooled placebo-corrected blood pressure-lowering effects were 5/2 mm Hg and 7/5 m

197 ailable were more likely to use at least one blood pressure-lowering medicine (adjusted odds ratio [O

198 ountries do not have access to more than one blood pressure-lowering medicine and, when available, th

199 Ensuring access to affordable blood pressure-lowering medicines is essential for contr

200 0.0001) than were those in communities where blood pressure-lowering medicines were not available.

201 he availability, costs, and affordability of blood pressure-lowering medicines with data recorded fro

202 assess the availability and affordability of blood pressure-lowering medicines, and the association w

203 he benefit or risk associated with intensive blood pressure-lowering treatment can be established onl

204 syndrome criteria) and hypotension (systolic blood pressure </=90 mm Hg or mean arterial pressure </=

205 d withdrawal to achieve a sustained systolic blood pressure <10 mmHg, cardiac arrest.

206 l CVRFs (n = 740) was also defined as having blood pressure <120/80 mm Hg, fasting glucose <100 mg/dl

207 defined as no current smoking and untreated blood pressure <140/90 mm Hg, fasting glucose <126 mg/dl

208 estigation, such as prehospital differential blood pressure management, reversal of warfarin effects

209 cis-eGenes (ALDH2 for systolic and diastolic blood pressure, MCM6 and DARS for total cholesterol, and

210 ire swine with a femoral artery catheter for blood pressure measurement and a pulmonary artery cathet

211 ls provided 1,342,814 systolic and diastolic blood pressure measurements for a genome-wide associatio

212 ning for preeclampsia in pregnant women with blood pressure measurements throughout pregnancy.

213 naires and fasting blood, anthropometric and blood pressure measurements were obtained at baseline, 6

214 tality, and the well-established accuracy of blood pressure measurements, the USPSTF found adequate e

215 isfaction with their blood-pressure care and blood-pressure medications, and adherence to blood-press

216 nd no significant difference in adherence to blood-pressure medications.

217 blood-pressure medications, and adherence to blood-pressure medications.

218 Ambulatory blood pressure monitoring (ABPM) is the preferred method

219 ssions for >/=1 minute and invasive arterial blood pressure monitoring before and during CPR between

220 ated quality-of-life questionnaires, 24-hour blood pressure monitoring, and polysomnography at the en

221 s, considering office and 24-hour ambulatory blood pressure monitoring, respectively, whereas no pati

222 retic peptide-associated genetic variants on blood pressure (n=27 059).

223 Blood pressure, non-fasting blood sugar, body mass index

224 ive medications while maintaining controlled blood pressure occurred in 41 of 49 patients from the ga

225 ulation, we defined hypertension as systolic blood pressure of at least 140 mm Hg, or diastolic blood

226 pressure of at least 140 mm Hg, or diastolic blood pressure of at least 90 mm Hg, or self-reported an

227 those who were assigned to a target systolic blood pressure of less than 120 mm Hg (intensive treatme

228 tensive treatment, which targeted a systolic blood pressure of less than 120 mm Hg, were similar to t

229 zed assessment, to achieve a target systolic blood pressure of less than 140 mm Hg to reduce the risk

230 ischemic attack to achieve a target systolic blood pressure of less than 140 mm Hg to reduce the risk

231 above 150 mm Hg to achieve a target systolic blood pressure of less than 150 mm Hg to reduce the risk

232 ated, with no detrimental effect on systemic blood pressure or hepatic perfusion.

233 sure 160 vs 110 mm Hg) but not for diastolic blood pressure or lipid measures with VTE.

234 I: 1.05, 1.70), and new-onset high diastolic blood pressure (OR: 1.25; 95% CI: 0.99, 1.58) at age 16

235 95% CI: 1.58, 3.02), new-onset high systolic blood pressure (OR: 1.34; 95% CI: 1.05, 1.70), and new-o

236 adults aged 60 years or older with systolic blood pressure persistently at or above 150 mm Hg to ach

237 sk factors (body mass index, fat mass index, blood pressure, physical activity, smoking, and alcohol

238 sk factors in midlife (specifically elevated blood pressure, physical inactivity, smoking, and poor g

239 These data suggest that the lowest blood pressure possible is not necessarily the optimal t

240 UV-A has been reported to lower blood pressure, possibly through nitric oxide (NO) produ

241 litus, obstructive sleep apnea, and elevated blood pressure predispose to AF, and each factor has bee

242 Conclusion Blood pressure readings, blood draws, injections, and nu

243 s placebo-corrected 24-h systolic ambulatory blood pressure reduction after 4 weeks and analysis was

244 nostic significance of dIVH in the Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage T

245 ndings highlight new biological pathways for blood pressure regulation enriched for genes expressed i

246 ng on muscle pump activation associated with blood pressure regulation was explored.

247 l processes such as apoptosis, inflammation, blood pressure regulation, and cancer progression and me

248 APOL1 risk alleles' association with blood pressure-related traits was tested in the discover

249 age rate of change in systolic and diastolic blood pressure, respectively, whereas family SES did not

250 f cardiovascular disease and normal systolic blood pressure (SBP < 130 mmHg).

251 33, OR7-7.9% = 1.86, OR8%+ = 3.22), systolic blood pressure (SBP) (ORper 10mmHg+ = 1.19), and insulin

252 o test the hypothesis that elevated systolic blood pressure (SBP) across its usual spectrum is associ

253 Aortic Transcatheter Valve) who had systolic blood pressure (SBP) and an echocardiogram obtained 30 d

254 ex (GI) and glycemic load (GL) with systolic blood pressure (SBP) and diastolic blood pressure (DBP)

255 (WC), waist-to-height ratio (WHtR), systolic blood pressure (SBP) and diastolic blood pressure (DBP).

256 s and control subjects (P = 0.040); systolic blood pressure (SBP) did not differ (P = 0.86).

257 tial benefits or risks of intensive systolic blood pressure (SBP) lowering are unclear.

258 kidney disease (CKD) with intensive systolic blood pressure (SBP) lowering is unclear.

259 Patients with an office systolic blood pressure (SBP) of 150 mm Hg or greater and less th

260 disease (ASCVD) risk to personalize systolic blood pressure (SBP) treatment goals is a topic of incre

261 The causal relationship between systolic blood pressure (SBP), calf electromyography (EMG), and r

262 167653, p38 MAPK inhibitor, reduced systolic blood pressure (SBP), urinary albumin excretion, segment

263 ukin-6 (Spearman r=0.33, P<0.0001), systolic blood pressure (Spearman r=0.28, P<0.0001), body mass in

264 BPM) is the preferred method to characterize blood pressure status.

265 eart failure, warfarin, age, race, diastolic blood pressure, stroke), and observed that all major ICH

266 an independent association between post-TAVR blood pressure, systemic arterial load, and mortality.

267 We report genetic association of blood pressure (systolic, diastolic, pulse pressure) amo

268 Intracoronary saline infusion did not affect blood pressure, systolic, or diastolic left ventricular

269 However, evidence-based blood pressure targets during pediatric CPR remain an im

270 ussion of the benefits and harms of specific blood pressure targets with the patient.

271 For both blood pressure targets, an identical shape of the J curv

272 e challenged the appropriateness of accepted blood pressure targets.

273 rs of contact showed greater improvements in blood pressure than control groups: -6.4 mm Hg (95% CI,

274 hborhoods was associated with lower systolic blood pressure than was consistent residence in low-inco

275 e biological effects of sodium intake beyond blood pressure.The DASH-Sodium Trial randomly assigned i

276 comparable cardiovascular risk profiles and blood pressure throughout the study.

277 ty, diabetes, hypertriglyceridemia, and high blood pressure to assign them to metabolic risk categori

278 ent study, we examined racial differences in blood pressure trajectories across early childhood in a

279 revealed no abnormalities in heart rate and blood pressure variability however the sympathetic skin

280 Systolic blood pressure, waist circumference (WC), and fasting bl

281 indexed as a composite of seven biomarkers [blood pressure, waist circumference, hemoglobin A1c (HbA

282 At initial clinic visit, her blood pressure was 138/84 with an unremarkable cardiovas

283 ntihypertensive medication, and the systolic blood pressure was 14.8 mm Hg (95% confidence interval,

284 Mean office blood pressure was 184/109 mm Hg (18/14) at baseline and

285 Blood pressure was assessed on 6 occasions between the a

286 ate of change in both systolic and diastolic blood pressure was greater among African-American childr

287 Blood pressure was measured in the supine position by us

288 graft function (P = 0.002) although abnormal blood pressure was not a significant predictor.

289 pill was 19 mm Hg (95% CI 14-23), and office blood pressure was reduced by 22/13 mm Hg (p<0.0001).

290 After 6 mmol of KNO3, systolic blood pressure was reduced by a maximum of 17.9 (95% CI

291 activity and pharmacological manipulation of blood pressure, we show that veterans with PTSD have aug

292 s with a higher BMI (>35 kg/m(2)) had higher blood pressures, were younger, and were more often women

293 enal sympathetic nerve activity and arterial blood pressure whereas equi-osmotic mannitol/sorbitol di

294 Last, spironolactone acutely lowered blood pressure, which was dependent on smooth muscle cel

295 es indicate a role for ANP as a regulator of blood pressure with conflicting results for BNP.

296 individually associated with lower systolic blood pressure with significant (P<0.00076) effect sizes

297 placebo-corrected reduction in systolic 24-h blood pressure with the quadpill was 19 mm Hg (95% CI 14

298 tudies of 2 well-accepted surrogate markers [blood pressure within sodium intake and cardiovascular d

299 t, glucose, triacylglycerol, cholesterol and blood pressure, without altering heart rate; changes in

300 exercise cardiac power output (mean arterial blood pressure x cardiac output) and functional capacity